ALESSANDRO GONCALVES CAMPOLINA

(Fonte: Lattes)
Índice h a partir de 2011
8
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder

Filtros

Limpar filtros

Configurações

Resultados de Busca

Agora exibindo 1 - 10 de 55
  • conferenceObject
    A Comparative Cost Analysis Study of Robotic and Video-Assisted Lobectomy: Results of Randomized Controlled Trial (Bravo Trial)
    (2021) TERRA, R.; TRINDADE, J.; CAMPOLINA, A.; ARAUJO, P. H. De; CAMPOS, J. R. De; PEGO-FERNANDES, P.
  • conferenceObject
  • article 7 Citação(ões) na Scopus
    Palliative cancer care: costs in a Brazilian quaternary hospital
    (2022) ROZMAN, Luciana Martins; CAMPOLINA, Alessandro Goncalves; LOPEZ, Rossana Mendoza; CHIBA, Toshio; SOAREZ, Patricia Coelho De
    Palliative care (PC) improves the quality of life of patients with diseases such as cancer, and several studies have shown a reduction in costs among patients who use PC services when compared with those receiving standard oncological treatments. Most studies on PC costs are carried out in high-income countries. There is a lack of these types of studies in middle-income and low-income countries and of better evidence about this intervention. Objective To describe resource utilisation and costs among patients with cancer in a Brazilian quaternary hospital by cancer localisation and per month of treatment before death. Methods This study is a description of retrospective costs to estimate the costs of formal healthcare sector associated with PCs, from the perspective of a public quaternary cancer hospital. Unit costs were estimated using microcosting and macrocosting approaches. Setting/Participants Patients older than 18 years old who died from 2010 to 2013 and who had at least two visits in PC and/or made use of hospice care. Results Among the 2985 patients included in the study, the average cost per patient was US$12 335, ranging from US$8269 for patients with pancreatic cancer to US$19 395 for patients with brain cancer. The main costing item was hospital admission (47.6% of the total cost), followed by hospice care (29.5%) and medical and other supplies (11.1%). Conclusions The study clarified the direct medical costs and the profile and use of resources of patients with cancer who need PC, and can help in the planning and allocation of resources in cancer care.
  • article
    Health Economic Evaluations of Cancer in Brazil: A Systematic Review
    (2018) CAMPOLINA, Alessandro G.; YUBA, Tania Y.; DECIMONI, Tassia C.; LEANDRO, Roseli; DIZ, Maria del Pilar Estevez; NOVAES, Hillegonda M. D.; SOAREZ, Patricia C. de
    Background: A large number of health economic evaluation (HEE) studies have been published in developed countries. However, Brazilian HEE literature in oncology has not been studied. Objective: To investigate whether the scientific literature has provided a set of HEE in oncology capable of supporting decision making in the Brazilian context. Methods: A systematic review was conducted to identify and characterize studies in this field. We searched multiple databases selecting partial and full HEE studies in oncology (1998-2013). Results: Fifty-five articles were reviewed, of these, 33 (60%) were full health economic evaluations. Type of cancers most frequently studied were: breast (38.2%), cervical (14.6%), lung (10.9%) and colorectal (9.1%). Procedures (47.3%) were the technologies most frequently evaluated. In terms of the intended purposes of the technologies, most (63.6%) were treatments. The majority of the incremental cost-effectiveness ratios (ICERs) reported have been below the cost-effectiveness threshold suggested by the World Health Organization (WHO). Conclusions: There has been an increase in the number of HEEs related to cancer in Brazil. These studies may support decision-making processes regarding the coverage of and reimbursement of healthcare technologies for cancer treatment in Brazil.
  • conferenceObject
    SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS IN CANCEROLOGY IN BRAZIL BETWEEN 1980 AND 2013
    (2014) YUBA, T. Y.; DECIMONI, T. C.; LEANDRO, R.; CAMPOLINA, A. G.; SOAREZ, P.
  • article 9 Citação(ões) na Scopus
    Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation
    (2018) RAMOS, Marcelo Cristiano de Azevedo; FOLGUEIRA, Maria Aparecida Azevedo Koike; MAISTRO, Simone; CAMPOLINA, Alessandro Goncalves; SOAREZ, Patricia Coelho de; BOCK, Geertruida Hendrika de; NOVAES, Hillegonda Maria Dutilh; DIZ, Maria Del Pilar Estevez
    OBJECTIVE: To analyze the cost effectiveness of the diagnostic program for the germline mutation in BRCA1/2 genes and of preventative strategies for the relatives of patients diagnosed with ovarian cancer associated with this mutation. METHODS: The study analyzed the cost effectiveness by developing an analysis of the Markov decision process from the perspective of the National Health System. The strategies compared reflect upon the adoption of genetic testing and preventative strategies for relatives or the usual care currently proposed. The incremental cost-effectiveness ratio was expressed in terms of cost per case avoided. The sensitivity analysis was performed in a univariate and deterministic manner. RESULTS: The study showed increments for effectiveness and for costs when performing genetic testing and adopting prophylactic measures for family members. The incremental cost-effectiveness ratio was estimated at R$908.58 per case of cancer avoided, a figure considered lower than the study's cost-effectiveness threshold (R$7,543.50). CONCLUSIONS: The program analyzed should be considered a cost-effective strategy for the national situation. Studies in various other countries have reached similar conclusions. One possible ramification of this research might the need to perform a budgetary-impact analysis of making the program one of the country's health policies.
  • article 1 Citação(ões) na Scopus
    Cost-effectiveness analysis of trastuzumab for early breast cancer in Brazil
    (2022) BOTELHO, Carlos Henrique; ESTEVEZ-DIZ, Maria Del Pilar; CAMPOLINA, Alessandro Goncalves
    Background: Adjuvant chemotherapy with trastuzumab for HER2 positive breast cancers has brought considerable benefits to disease-free survival and overall survival. Objective: To conduct a cost-effectiveness analysis of the treatment of patients with early and locally advanced HER2 positive breast cancer, within the scope of the Brazilian public health system, comparing adjuvant chemotherapy with and without trastuzumab, for 1 year of treatment. Methods: A 4-state Markov model was developed to estimate strategy costs and outcomes. Results: Based on the proposed model, we verified an incremental benefit of trastuzumab therapy compared to treatment without trastuzumab with 0.84 quality-adjusted life years (QALY) and 1.16 life years gained (LYG). The use of adjuvant chemotherapy with trastuzumab has an ICER of US$19,599.26 for each quality-adjusted life year and US$14,180.68 for each life year gained in relation to chemotherapy without trastuzumab. Conclusion: In Brazil, adjuvant chemotherapy with trastuzumab may be considered cost-effective only if a cost-effectiveness threshold is stipulated with the value starting at three times the Brazilian GDP per capita for QALY or two times the Brazilian GDP per capita for LYG, from health system perspective.
  • article 16 Citação(ões) na Scopus
    Quality of life in a sample of Brazilian adults using the generic SF-12 questionnaire
    (2018) CAMPOLINA, Alessandro Goncalves; LOPEZ, Rossana Veronica Mendoza; NARDI, Elene Paltrinieri; FERRAZ, Marcos Bosi
    Objective: This study describes the summary scores of the Short Form-12 (SF-12) questionnaire, according to socio-demographic factors obtained in a probabilistic and representative sample of the Brazilian urban population. Method: Five thousand (5,000) individuals, over the age of 15, were assessed in 16 capital cities, in the five regions of the country. The selection of households was random. Face-to-face approach was applied in the household interviews. The SF-12 questionnaire was used to assess quality of life. Demographic and socioeconomic characteristics were also evaluated: gender, age, marital status, skin color, region of the country and use of the public health service. Results: The mean value (SD) of the SF-12 for the entire population was 49.3 (8.7) for the physical component (PCS-12) and 52.7 (9.7) for the mental component (MCS-12). Statistical differences were found for gender (PCS-12 and MCS-12), age (PCS-12) and working status (PCS-12 and MCS-12). Women, elderly, widowed and unemployed individuals, those with lower income and with complaints in the last seven days showed lower mean values (PCS-12 and MCS-12). Conclusion: From this point forward, we can provide the basis for comparisons with future research that use the SF-12 for quality of life assessment in Brazil. The Brazilian population has a lower degree of quality of life related do the physical component, and the SF-12 is a useful and discriminative instrument for assessing quality of life in different socio-demographic groups.
  • conferenceObject
    ECONOMIC ANALYSIS OF HEPATO CELLULAR CARCINOMA TREATMENT BY SEVERITY OF DISEASE
    (2017) TANI, J. A.; CAMPOLINA, A. G.; DECIMONI, T. C.; TOMITAO, M.; FERREIRA, L. A.
  • bookPart
    Regulação clínica e avaliação de tecnologias no Brasil
    (2022) CSIPAK, Angélica Richart; MAGATON, Érida Aparecida Pinto; CAMPOLINA, Alessandro